Founded with the mission to revolutionize the diagnosis of Lyme disease, Veramarx aims to provide an accurate and early-stage diagnostic test for one of the fastest-growing infectious diseases in the US and Western Europe. The company offers a proprietary immunoassay that measures ten inflammatory biomarkers, achieving a 92% sensitivity rate at the critical early stage of infection. This is a significant improvement over current tests, which miss over 60% of early-stage cases. Veramarx focuses on ensuring effective treatment by enabling timely and accurate diagnosis.
Notable figures associated with Veramarx include leading experts in infectious diseases and diagnostics. The company has garnered attention from key investors in the healthcare sector, bolstering its research and development efforts. Veramarx's most significant achievement is its patented diagnostic test, which has the potential to transform Lyme disease management and improve patient outcomes significantly. By addressing a critical gap in early detection, Veramarx is poised to make a substantial impact on public health.
